M2Bio Sciences 

Wuhan General Group (China), Inc., through its various subsidiaries, is engaged in the research, development, and commercialization of a wide array of cannabidiol (CBD)-derived products. These products are sold to pharmacies under the Dr. AnnaRx brand. Additionally, the company is actively pursuing the exploration and development of innovative psilocybin-based therapies intended to assist patients grappling with mental illnesses. Its product line targets a range of medical applications, including but not limited to cancer, psychological disorders, and chronic pain. The company maintains its principal office in Pointe-Claire, Canada.